Karyopharm Therapeutics Inc. completed a $30 million private placement with RA Capital Management on March 24, 2026. The transaction involved the sale of approximately 1.03 million shares of common stock at $6.785 per share, 3.39 million pre‑funded warrants at $6.7849 per warrant, and 4.42 million warrants covering 10 shares each. The warrants are exercisable at $10 per share and expire 30 days after the company announces the topline results of its Phase 3 XPORT‑EC‑042 trial.
The proceeds will be used to support ongoing and future clinical trials and for general corporate purposes. The financing also satisfies a key condition to activate previously agreed amendments and forbearance on the company’s credit facilities and convertible notes, thereby extending liquidity into late Q3 2026. With an annual cash burn of roughly $75 million, the capital raise provides a critical buffer for the company’s pipeline development.
On the same day, Karyopharm reported mixed topline results from its pivotal Phase 3 SENTRY trial for selinexor in frontline myelofibrosis. The study met the co‑primary endpoint of spleen volume reduction but missed the symptom score improvement endpoint. Analysts at Jefferies noted that missing one of the co‑primary endpoints could make it difficult for the company to secure conventional approval for Xpovio in myelofibrosis, raising concerns about the drug’s future revenue potential.
In addition to the trial results, the company announced the voluntary withdrawal of the accelerated approval of Xpovio’s diffuse large B‑cell lymphoma (DLBCL) indication at the FDA’s request. The withdrawal allows Karyopharm to reallocate resources from a program that was no longer feasible to more commercially and clinically viable indications, such as multiple myeloma and endometrial cancer.
Financially, Karyopharm’s trailing‑twelve‑month revenue stands at $146.07 million, with a three‑year revenue growth rate of –22.6%. The company’s margins remain negative and revenue per share has declined over the past five years. The private placement also opens the possibility of an additional $44 million if the warrants are exercised, providing further upside to the company’s liquidity position.
The announcement was met with a negative market reaction, largely driven by the mixed SENTRY trial results. While the private placement offered a short‑term liquidity boost, the clinical setback and the DLBCL withdrawal underscore the company’s ongoing challenges and the need for continued investment in its pipeline to achieve a sustainable revenue trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.